Tabelecleucel (tab-cel®)

First-in-class allogeneic T-cell therapy.

With European Commission marketing authorization, Atara is the first company to ever receive approval for an allogeneic T-cell immunotherapy.* This landmark milestone opens the door for further allogeneic approaches in oncology, autoimmune conditions, and beyond.

*Tab-cel® is only approved in the European Union

  • An innovative approach for at-risk transplant patients.

    Tabelecleucel (tab-cel®) is being developed for relapsed or refractory EBV-positive post-transplant lymphoproliferative disease (PTLD), an ultra-rare and aggressive hematologic cancer. EBV+ PTLD patients who fail initial therapy face a poor prognosis and dismal median survival of only weeks to a few months. Tab-cel® is an allogeneic, EBV-specific T-cell immunotherapy which targets EBV-infected cells.

  • ayden

    Ayden, PTLD advocate, pneumococcal strep A19 survivor, kidney transplant recipient

  • What is post-transplant lymphoproliferative disease?

  • EBV-positive post-transplant lymphoproliferative disease (EBV+ PTLD) is a rare, acute, and potentially deadly hematologic malignancy that occurs after transplantation when a patient's T-cell activity is compromised by immunosuppression. It can impact patients who have undergone solid-organ transplant (SOT) or an allogeneic hematopoietic cell transplantation (HCT).

Other indications under investigation

  • We’re also conducting a Phase 2 multi-cohort study including EBV+ PTLD with central nervous system involvement, EBV+ acquired & primary immunodeficiency lymphoproliferative diseases (AID-LPD and PID-LPD), EBV+ leiomyosarcoma, EBV+ PTLD where standard first line therapy is not appropriate, and other EBV-associated diseases (NCT04554914, 205 study).

  • Lab phials Close-up of automated lab sampling equipment
  • Our innovations are made possible by patients.

    The patients and investigators who participate in our clinical studies are essential to how we develop new therapies. Learn more about our ongoing studies.

Stay up to date.